Watch for ABCL635 late-stage development initiation in 2027 and 12-week/OLE data in early 2027; the Phase 2 efficacy data appear superior to approved NK3R antagonists, but the company remains pre-revenue on its own pipeline and the $200M raise adds dilution.
Drugs in focus
ABCL drug pipeline →ABCL635
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
- Next catalyst
- None dated
What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.
- ● ABCL575 2/10 Phase 1 Named in filing
- ● ABCL688 2/10 Preclinical / IND-enabling Named in filing
- ● ABCL385 1/10 No data found for ABCL385 Named in filing
- ● ABCL386 0/10 Unknown / Not publicly disclosed Named in filing
- ● ABCL646 0/10 Unknown / Not found Named in filing
- 1 more · All ABCL drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $12.46entry
- T+1 · 6d ago −4.09%α −5.41% · $11.95
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbCellera reported Q3 2026 revenue of $10.6M (up 19% YoY from $9.0M) and a net loss of $40.8M ($0.13 per share), narrower than the $57.1M loss in Q3 2025. The company announced positive Phase 2 data for ABCL635 in menopausal hot flashes, completed a $200M equity offering, and ended the quarter with over $890M in available liquidity. No EPS or revenue consensus was provided, so no beat/miss rating is assigned.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $10.6M vs $9.0M in Q3 2025 (+19% YoY)
- Net loss $40.8M ($0.13 per share) vs $57.1M ($0.19) in Q3 2025
- Positive top-line Phase 2 data for ABCL635 in menopausal vasomotor symptoms
- Completed $200M offering of common shares and pre-funded warrants at $9.75 per share
- Ended Q3 with over $790M in cash and marketable securities, over $890M total liquidity
- Partner-led programs with downstreams declined to 34 from 44 at Dec 2025
- R&D expenses $43.5M vs $55.0M in Q3 2025; SG&A $13.6M vs $25.0M
- Year-to-date operating cash flow positive at $19.3M vs negative $96.5M in prior year
Financial Impact
Revenue up 19% YoY; net loss narrowed 29% YoY; cash position strengthened to $890M after $200M equity raise
Risk Factors
- Pre-revenue biotech with no approved products; net loss continues
- ABCL635 Phase 3 development and regulatory approval still years away
- Partner-led pipeline declining (44 to 34 programs with downstreams)
- Dilution from $200M equity offering (~20M shares at $9.75)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001703057-26-000058 |
| Document: abcl-20261109.htm | 0001703057-26-000058 |
| Document: a2026q3businessupdatenov.htm | 0001703057-26-000058 |
| Document: 0001703057-26-000058-index-headers.html | 0001703057-26-000058 |
| Document: 0001703057-26-000058-index.html | 0001703057-26-000058 |
| Document: 0001703057-26-000058.txt | 0001703057-26-000058 |
| 8-K Data (Synthetic) | 0001703057-26-000058 |
Track record
16 reports on ABCL
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $12.46 Now $11.12 −10.75% settles Feb 8
- Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
- Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
- Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
- Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers